Sortilin enhances fibrosis and calcification in aortic valve disease by inducing interstitial cell heterogeneity.
Farwah IqbalFlorian SchlotterDakota Becker-GreeneAdrien LupieriClaudia GoettschJoshua D HutchesonMaximillian A RogersShinsuke ItohArda HaluLang Ho LeeMark C BlaserAndrew K MlynarchikSumihiko HagitaShiori KuraokaHao Yu ChenJames C EngertLivia S A PassosPrabhash K JhaEric A OsbornFarouc A JafferSimon C BodySimon C RobsonGeorge ThanassoulisMasanori AikawaSasha A SinghAbhijeet Rajendra SonawaneElena AikawaPublished in: European heart journal (2023)
Sortilin promotes CAVD by mediating valvular fibrosis and calcification, and a newly identified phenotype (IMO-VIC). This is the first study to examine the role of sortilin in valvular calcification and it may render it a therapeutic target to inhibit IMO-VIC emergence by simultaneously reducing inflammation, fibrosis, and calcification, the three key pathological processes underlying CAVD.